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Background: Antibodies against the programmed death-1 (PD-1) receptor and its ligand (PD-L1) have
been recently approved for small-cell lung cancer (SCLC) treatment. Circulating tumour cells (CTCs) have
emerged as an appealing liquid biopsy candidate that could enhance treatment decision-making in systemic
therapy for SCLC patients. Several current technologies enrich CTCs using specific surface epitopes, size,
rigidity, or dielectric properties. However, they are hampered by the heterogeneity of the enriched cells from
blood samples.
Methods: We evaluated two CTC enrichment systems: EpCAM conjugated to magnetic beads and a
microfluidic device (Parsortix, Angle plc). PD-L1 expression was evaluated on the isolated CTCs. Twentythree blood samples were collected from 21 patients with SCLC. PD-L1 expression was determined on
CTCs through immunofluorescent staining.
Results: CTCs were found in 14/23 (60.9%) of the samples, with 11/23 (47.8%) through EpCAMcoated magnetic beads (range, 4–1,611 CTCs/8 mL; median =5) and 11/20 (55.0%) using the Parsortix
system (range, 1–165 CTCs/8 mL; median =4). Notably, a total of 17 EpCAM-negative CTCs were isolated
using the Parsortix system. PD-L1 expression was detected on 268 of the 3,501 (7.7%) CTCs isolated with
EpCAM-coated beads and in 33/366 (9.0%) of the CTCs isolated with the Parsortix system. No vimentin
expression was observed in any of the detected CTCs.
Conclusions: Overall, we identified a population of EpCAM-negative SCLC CTCs and showed that
PD-L1 expression can be assessed on CTCs from SCLC patients. Comparison to tumour and treatment
outcomes is needed to validate the potential of CTCs as an alternative sample for the assessment of PD-L1
expression in SCLC.
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Introduction
Small-cell lung cancer (SCLC) is a highly aggressive
subtype of lung cancer that accounts for approximately 15%
of all lung cancers (1). It is characterised by rapid cellular
proliferation and early extensive metastases (2). About 60%
of patients have an extensive-stage disease at the time of
diagnosis (3). Despite extensive studies, limited therapeutic
advances have done little to improve SCLC patients’
outcomes.
Chemotherapy and/or radiotherapy remain the
principal treatment modalities for SCLC patients, who
often show a high response to treatment early on (4-6).
However, recurrence occurs in most cases, resulting in a
poor prognosis. The 5-year overall survival (OS) rate for
early-stage disease is around 15–27%, and for metastatic
disease, it is reduced to ~2.8% (4-7). The use of monoclonal
antibodies to block the interaction between programmed
death-1 (PD-1) and its ligand (PD-L1) has appeared
recently as a treatment option in non-small cell lung cancer
(NSCLC), and more recently, SCLC (8,9). Expression of
PD-L1 by tumour cells allows them to escape immune
effector mechanisms (10). Recently, the anti-PD-L1
agents atezolizumab and durvalumab in combination with
chemotherapy gained US Federal Drug Administration
(FDA) approval as a first-line treatment for extensivestage SCLC. Despite immune checkpoint inhibitors (ICIs)
becoming a primary component of SCLC treatment, their
efficacy is modest, with only 2 months of OS benefits and
limited to a small subset of patients (8,9,11). Hence, there
is a need to identify biomarkers that will help determine
a subgroup of SCLC patients most likely to benefit from
these treatments.
Generally, expression of PD-L1 is assessed on fine-needle
aspiration biopsy or core needle biopsy tissue specimen.
However, acquisition of tumour tissue is both laborious and
invasive for patients. In metastatic SCLC, surgical resection
and repeat tumour biopsies are not standard of care and
consequently, there can be insufficient tissue for clinical
analysis (12,13). Circulating tumour cells (CTCs) offer an
appealing liquid biopsy modality for SCLC due to their
abundance in the blood of these patients. CTCs can serve
as a minimally invasive and serially acquirable substitute for
tumour biopsies for tumour characterisation and evaluation
of PD-L1 expression in SCLC (14,15).
CTCs are malignant cells shed into the blood by both
primary and metastatic solid tumours and their presence
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in circulation represents a critical step in the metastatic
process (16,17). CTCs can reflect the heterogeneity of
SCLC tumours because they arise from different tumour
sites (18,19). SCLC is distinguished by exceedingly high but
variable numbers of CTCs ranging from single to thousands
of CTCs per 7.5 mL of peripheral blood compared with
other solid malignancies (20). The number of CTCs present
are prognostic and reflect the changing disease burden
throughout treatments (21,22). Yet, detection of CTCs
after isolation is a challenge due to tumoural heterogeneity.
Different well-established approaches to isolate and identify
SCLC CTCs with different definitions of tumour cells have
been published with detection rates ranging from 60% to
96% (23-25).
CellSearch, an EpCAM-based system, remains the
only FDA-approved system and the most used SCLC
CTC isolation platform in the clinical setting (26). With
the CellSearch platform, CTCs are detectable in most
SCLC patients due to the abundance of high EpCAM
expressing CTCs (20-22). However, some CTCs might not
express EpCAM or might have downregulated EpCAM
and therefore remain undetectable with this method. To
overcome the above limitation, alternative strategies based
on the biophysical properties of the cells other than EpCAM
protein expression are necessary (27). Such non-markerbased strategies may allow for broader coverage of CTCs
subpopulations. Currently, there are several developed
size-based platforms (28). Amongst them, the Parsortix
system, which isolates cells based on a combination of size
and deformability, has been shown to isolate CTCs where
CellSearch was unable to (29).
The assessment of PD-L1 on CTCs (PD-L1+ CTCs)
has been extensively studied in NSCLC (30) but to our
knowledge, no exhaustive report exists for SCLC. We,
therefore, developed an EpCAM targeting magnetic
bead-based CTC isolation method as a surrogate for
CellSearch, the gold standard for CTC enumeration.
Using our immunomagnetic isolation technique, we
compared detection rates of CTCs isolated using EpCAMbased immunomagnetic capture to those isolated using
the Parsortix system. Secondly, we established a workflow
to determine the prevalence of PD-L1+ CTCs in SCLC
utilising EpCAM-coated magnetic beads and the Parsortix
system. We present the following article in accordance with
the MDAR reporting checklist (available at https://tlcr.
amegroups.com/article/view/10.21037/tlcr-21-819/rc).
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Figure 1 Workflow for assessment of PD-L1 expression on SCLC patient CTCs. CTC isolation workflow: blood is collected from SCLC
patients and processed through Parsortix system and EpCAM-coated magnetic beads. Enriched cells are collected, permeabilised and fixed,
and then immunostained with immunofluorescence markers for imaging. Medical elements in this image are from smart.servier.com. CTCs,
circulating tumour cells; PBMCs, peripheral blood mononuclear cells; Ab-bead, antibody conjugated beads; PFA, paraformaldehyde; SCLC,
small-cell lung cancer.

Methods
Patient recruitment and sample collection
For this pilot study, a total of 21 SCLC patients were
recruited in the study between August 2018–March 2021 at
Sir Charles Gairdner Hospital (SCGH) and Fiona Stanley
Hospital (FSH) in Perth, Western Australia. Written
informed consent was obtained from all patients under
approved Human Research Ethics Committee protocols
from Edith Cowan University (No. 18957) and Sir Charles
Gairdner Hospital (No. 2013-246, RGS0000003289). The
study was conducted in accordance with the Declaration of
Helsinki (as revised in 2013). At least 8 mL of blood was
collected from each patient into K2EDTA (BD, Franklin
Lakes, NJ, USA) tubes for CTC analysis. Samples were
processed within 6 hours of blood collection. Demographic
and clinical information such as age, gender, disease stage,
performance status, smoking status, number of metastases,
and type of treatment of patients were collected. Smoking
status was collected as smokers and non-smokers. The
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smokers included those who smoked at least 10 packs a year
(i.e., one pack a day for 10 years) either former or current.
Enrichment and identification of CTCs
Plasma was isolated from samples by centrifugation for
20 minutes at 300 ×g before CTC enrichment with antiEpCAM coated magnetic beads (Appendix 1). The CTC
capture process was carried out using anti-EpCAM beads in a
modified protocol developed in our laboratory (31). Captured
cells were immunostained with antibody cocktail containing
three mixed pan-cytokeratin antibodies to ensure broad
cytokeratin coverage, CD45, CD16, and CD66b antibodies
to exclude hematopoietic cells and anti-PD-L1 antibody
(28.8) to detect PD-L1 expression as detailed in Appendix 1.
In parallel, another blood sample was processed using
the Parsortix system at 99-mbar through a 6.5-μm cassette
(Figure 1). Enriched cells were harvested according to the
manufacturer’s instructions and fixed for 10 minutes at room
temperature with 4% paraformaldehyde (PFA). A total of
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Table 1 Clinical and demographic characteristics of patients
Variables
Age (years), median (IQR)

Frequency (n)

Percentage (%)

67.5 (63.5–83.0)

–

443

spiked into white blood cells (WBCs) from healthy control
donors as detailed in Appendix 1.
Imaging and image analysis

Age group (years)
<67

9

42.9

≥67

12

57.1

Male

9

42.9

Female

12

57.1

Limited

2

9.5

Extensive

19

90.5

0

9

42.9

1

8

38.1

≥2

4

19.0

Yes

20

95.2

No

1

4.8

1

5

23.8

≥2

16

76.2

Chemotherapy

7

33.3

Chemotherapy + ICI

13

61.9

Radiation

1

4.8

Gender

Disease stage

Performance status (ECOG)

Smoking status

Number of metastasis

Type of treatment

IQR, interquartile range; ECOG, Eastern Cooperative Oncology
Group; ICI, immune checkpoint inhibitor.

8–9 mL of blood was processed through each method. To
increase the numbers of markers to be interrogated, such as
EpCAM expression separate from cytokeratins, vimentin,
and PD-L1 expression (29), we adapted the quenching and
re-staining protocol described by Adams et al. (32). This
protocol utilises borohydride to quench fluorescent signals
after an initial round of immunostaining followed by a
second round of staining for additional markers, allowing for
multi-phenotype analysis of CTCs. The PD-L1 detection,
quenching, and restaining methods were standardised using
MCF7, MCF7 induced with IFN-γ, MDA-MB-231 cell lines
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Slides were visualised and scanned using a Nikon Eclipse
Ti-E inverted fluorescent microscope (Nikon, Chiyoda,
Japan). Images were analysed using the NIS-Elements
Analysis software, version 5.21 (Nikon).
Statistical analysis
All data was entered into Microsoft Excel and analysed
with GraphPad Prism (version 8.0.2). Demographic data
is presented as numbers, ranges, or counts, percentages,
means, and medians where applicable using GraphPad
version 8. Cohen’s kappa test was used to analyse the
difference in CTC detection rates between EpCAM-coated
magnetic beads and the Parsortix system as well as an
agreement between the two isolation methods.
Survival analysis was performed using the KaplanMeier method and differences in patient survival rates were
determined using log-rank tests. Univariate and multivariate
Cox regression hazard models for OS were performed for
CTC count, number of metastases, Eastern Cooperative
Oncology Group (ECOG) performance status, sex, and age
using SPSS version 26. All survival plots were performed in
R (version 4.05) using the “survplot” package (33,34) with
P<0.05 considered statistically significant.
Results
Clinical characteristics of patients
A total of 23 blood samples were collected from 21 SCLC
patients for the analysis of the presence of CTCs before
the commencement of treatment. Blood samples for CTC
enumeration were collected before treatment in 19 patients,
while bloods were collected before treatment and at the
time of relapse in 2 patients. The clinical characteristics of
the study population are summarised in Table 1. Of the 21
SCLC patients in this study, 2 patients (9.5%) had limited
stage disease and 19 (90.5%) had extensive disease. The
median age of SCLC patients at the time of diagnosis was
67.5 (range, 63.5–83.0) years and there were 12 females and
9 males. Patients were treated with chemotherapy alone (n=7)
or in combination with either atezolizumab or durvalumab
(n=13). One patient was treated with cyberknife radiation.
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Figure 2 Representative images of SCLC CTCs identified by immunofluorescence staining. (A) CTCs enriched with Parsortix system.
Cells were immunostained with pan-cytokeratins and EpCAM (green), CD45/16/66b (pink), and TSA PD-L1 (cyan). (B) CTCs enriched
by EpCAM coated magnetic beads. Cells were immunostained with pan-cytokeratins (pCK, green), CD45/16/66b (pink), and TSA PD-L1
(cyan). WBC were included for comparison. Scale bar (top left) represents 10 μm. CTCs, circulating tumour cells; WBC, white blood cells;
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Figure 3 CTC counts in SCLC patients. Samples were processed with EpCAM-coated magnetic beads (n=23, green bars), and a proportion
of them (to the right of the dashed line) was also enriched for CTCs using the Parsortix system (n=20, blue bars). The number of cells on
each sample is indicated on top of the bars. *, indicate samples with CTC clusters. A contingency table comparing the number of positive
samples by each method and associated statistics have been inserted. CTC, circulating tumour cell; SCLC, small-cell lung cancer.

CTC enumeration and characterisation
CTCs were isolated from 23 blood samples using antiEpCAM immunomagnetic beads. Only 20 of these patients
had a second blood sample available for CTC isolation
using the Parsortix system. Enriched CTCs were identified
through immunofluorescence staining, as exemplified in
Figure 2. CTCs were detected in 11 of 23 (47.8%) samples
processed with EpCAM-coated magnetic beads [median
=5 (range, 1–1,611)] and in 11 of 20 (55.0%) samples
processed with the Parsortix system [median =4 (range,

© Translational Lung Cancer Research. All rights reserved.

1–165) (Figure 3). Combining both methods, CTCs were
found in 14/23 (60.9%) of the SCLC samples. Comparison
of CTC detection in the 20 matched samples using Cohen’s
kappa coefficient indicated a moderate agreement (к =0.51;
P=0.017) between the detection rate of the two methods. In
samples with a large number of CTCs (cases 1355 and 1360
in Figure 3), EpCAM beads recovered 10 times more CTC
than using Parsortix. However, six samples (1312, 1318,
1325, 1341, 1374, and 1434) exhibited a higher number
of CTC recovered using the Parsortix system than using
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Figure 4 Representative cells enriched with the Parsortix system. Cells were stained with pan-cytokeratins (pCK, green), EpCAM (red),
CD45/16/66b (pink) to identify classical SCLC CTCs, followed by fluorescence quenching and re-immunostained for PD-L1 expression
(cyan) and vimentin (orange). Scale bar (top left) represents 10 μm. CTCs, circulating tumour cells; WBC, white blood cells; SCLC, smallcell lung cancer.

EpCAM-coated beads.
CTC clusters were found in 6/23 of samples. Of the
6 samples with clusters, 3 samples were processed with
EpCAM beads only. The remaining 3 cluster-containing
samples were processed with both isolation methods,
where clusters were found in all three Parsortix samples
and 2/3 EpCAM beads samples (Figure 3). Additionally,
we found WBCs paired with single CTCs or with CTC
clusters in all 3 samples with clusters processed on the
Parsortix system, but not in any of the EpCAM-captured
samples (Figure 4, Figure S4). A subgroup of 14 samples
enriched using Parsortix was also assessed for the expression
of EpCAM and CK on CTCs separately, as well as for
vimentin expression (Figure 4). No vimentin expressing
CTCs were detected in any of the patients. A total of 17
EpCAM-negative CK-positive CTCs were detected in 3/14
(21.4%) patients, and these cells were always found as single
CTCs (Figure 4, Figure S5). Notably, in one sample (1374
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in Figure 3) only EpCAM-negative CTCs were detected,
which was consistent with the sample found to be negative
using the EpCAM-beads capturing approach.
PD-L1 expression on CTCs
PD-L1 expression was assessed on the 14 CTC-positive
samples found among the 23 blood samples analysed.
Overall, ≥2 PD-L1+ CTCs were detected in 7/23 (30.4%)
samples regardless of the isolation method. PD-L1+ CTCs
were found in 5 samples processed with EpCAM-coated
magnetic beads and in 3 samples processed with Parsortix
(Figure 5). PD-L1 expression was analysed on a total of 3,501
CTCs isolated with EpCAM-coated beads with 268 (7.7%)
found positive for PD-L1. In comparison, 33 of 366 (9.0%)
CTCs isolated on the Parsortix system expressed PD-L1.
Three of the 17 EpCAM-negative CTCs identified were
positive for PD-L1 expression.
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Figure 5 Comparison of PD-L1 expressing CTCs isolated by immunomagnetic beads and the Parsortix system. Bars represent counts in
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bars. CTCs, circulating tumour cells.
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numbers, median, and 95% CIs are indicated for each plot. CTCs, circulating tumour cells; CI, confidence interval; OS, overall survival.

Survival analysis
The median OS of patients after blood draw was 9.3
months (95% CI: 4.3–14.2 months). We assessed the
correlations of CTC counts with OS using the previously
validated thresholds of 2 and 50 CTC per 7.5 mL of blood
(24,35,36). Neither of the two CTC threshold groupings
showed statistically significant differences between the
clinical characteristic of the patients (Table S2). There was
no statistically significant difference in median OS between
patients with ≥2 CTCs compared to those with <2 CTCs
(5.5 vs. 8 months, P=0.276). However, patients with ≥50
CTCs had significantly shorter median OS compared
with those with <50 CTCs (4.0 vs. 10.9 months, P=0.033)
(Figure 6). Univariate Cox regression analysis revealed that
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≥50 CTCs was significantly associated with shorter OS (HR
=3.11; 95% CI: 1.01–9.32; P=0.043). Multivariate analysis
showed that ≥50 CTCs was an independent prognostic factor
for shorter OS (HR =6.15; 95% CI: 1.35–27.99; P=0.019)
(Table 2). Among the 14 SCLC patients with ≥2 CTCs, there
was no statistical difference in the survival of patients with
PD-L1-CTCs compared with patients with PD-L1+ CTCs
(10.9 vs. 4.0 months, P=0.103) (Figure S6).
Discussion
CTCs have emerged as appealing liquid biopsy candidates
that could enhance treatment decision-making (14,15).
In this study, we employed a size-based CTC enrichment
method, the Parsortix system, that has been demonstrated
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Table 2 Univariate and multivariate Cox hazard regression analysis
Variables
Age (years)

Sex

CTC count

Performance status (ECOG)

No of metastases

Groups

Univariate

Multivariate

HR (95% CI)

P value

HR (95% CI)

P value

≥67 (n=12)

–

–

–

–

<67 (n=9)

1.29 (0.43–3.87)

0.641

1.14 (0.27–4.77)

0.858

Male (n=9)

–

–

–

–

Female (n=12)

2.14 (0.17–6.50)

0.176

2.45 (0.64–9.35)

0.189

<50 (n=15)

–

–

–

–

≥50 (n =6)

3.11 (1.01–9.32)

0.043*

6.15 (1.35–27.99)

0.019*

0 (n=9)

–

–

–

–

1 (n=8)

1.26 (0.38–4.18)

0.194

0.45 (0.09–2.25)

0.337

≥2 (n=4)

2.62 (0.61–11.23)

0.480

4.23 (0.64–27.98)

0.134

1 (n=5)

–

–

–

–

≥2 (n=16)

2.79 (0.59–13.02)

0.230

3.56 (0.62–20.48)

0.156

*, P<0.05, considered statistically significant. HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group.

to harvest CTCs in a greater proportion in different tumour
types including SCLC (29,37-39). We also validated a
simple, rapid, and affordable method to detect CTCs based
on magnetic cell separation. We compared CTCs detection
rates between the two isolation methods, using matched
samples, and evaluated the potential of CTCs for PD-L1
expression other than SCLC biopsy tissue.
Both epitope-dependent and epitope-independent
enrichment methods have been shown to isolate high
numbers of CTCs in SCLC patients compared with other
types of cancers (40). The overall frequency of patients
with detectable CTCs in our study was 61%, in line with
previous reports in SCLC, showing detectable CTCs in
between 60–95% of patients. However, CTC detection
rate was higher in samples processed with the Parsortix
system (55%) compared to EpCAM-coated magnetic beads
(48%) in a matched comparison. Chudziak et al. (29) also
reported similar results reporting that cytokeratin positive
CTCs were detectable in all the 12 samples processed on
the Parsortix platform while CellSearch only detected
cytokeratin positive CTCs in 10 (83%) of the SCLC
patients tested. These results may be explained by the fact
that EpCAM-based isolation methods may fail to capture
EpCAM low/negative expressing CTCs. In line with this,
we demonstrated here that EpCAM negative CTCs were
isolated using Parsortix in 14.3% of the processed samples.
On the other hand, the number of Parsortix-isolated
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CTCs was lower those isolated using EpCAM-beads, in
particular for the two patients with the largest number of
CTCs. SCLC CTCs are relatively small, compared to other
carcinomas (ref) and may not be efficiently retained by the
Parsortix system which isolates CTCs based on size and
deformability (41).
It has been proposed that primary and metastatic tumours
release cells into the bloodstream through a process of the
epithelial to mesenchymal transition (EMT) (42). Given the
loss of EpCAM observed in CTCs isolated using Parsortix,
we assessed the potential expression of vimentin on these
cells. Results revealed the absence of vimentin in all the
CTCs interrogated. This result suggests that EMT is
not homogenously expressed in tumour cells within the
circulation of SCLC patients and supports the importance
of other types of motility shift such as amoeboid cell
invasion which has been demonstrated to be typical of
SCLC (43,44). Although, there are limited studies on
amoeboid tumour cell invasion in SCLC and lack of EMT
markers such as vimentin on SCLC CTCs suggest it might
be an important subject area for further studies.
Multiple studies in the last decade have demonstrated
that the presence of measurable CTCs in SCLC patients is
associated with shorter survival (24,36,45). The presence of
≥2 and ≥50 CTCs per 7.5 mL of blood from SCLC patients
before chemotherapy was highly significant for poor OS,
regardless of other clinical prognostic variables (24,36).
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Consistent with these studies (24,36,45), we found that
patients with ≥50 CTCs had significantly shorter median
OS compared with the <50 CTCs group.
The biology of clustered CTCs is an evolving area of
research. CTC clusters in the peripheral blood have been
reported in patients with SCLC (24). In this study, CTC
clusters were detected samples processed on the Parsortix
system and with EpCAM coated magnetic beads. The
number of cells within the CTC clusters detected on the
Parsortix were large, comprised of up to 8 CTCs and
involving WBCs, compared to 2–3 clustered CTCs detected
using the immunomagnetic beads. A number of studies have
shown the role of clusters in the migration and survival of
CTCs in breast and gastric cancer (38,46,47). However, no
studies have directly addressed how SCLC CTC clusters
may enable metastases and/or chemoresistance.
Until recently, far too little attention has been paid to
the expression of PD-L1 on CTCs in SCLC, compared
to its extensive study in NSCLC (30,48-51). This is
partly due to the early approval of ICIs for the treatment
of NSCLC and higher expression of PD-L1 protein in
NSCLC. On the other hand, there is a wide difference
in the prevalence of PD-L1 expression in tumour cells
of SCLC patients reported in the literature, ranging
from 0–86% (52,53). Even though ICIs combined with
chemotherapy were recently approved for SCLC treatment,
tumour PD-L1 expression has been demonstrated to be
a non-discriminatory biomarker (8,9,11). However, it is
possible that retaining PD-L1 might represent one of the
mechanisms that CTCs use to survive immune system
attack while in circulation and, therefore a better readout
of a pre-existing anti-tumour response. Previous studies in
melanoma and NSCLC have shown that PD-L1 expression
on CTCs a promising prognostic biomarker in patients
treated with ICIs, despite the lack of correlation with the
expression on matching tumours (54,55).
Our study is the first to evaluate PD-L1 expression
on CTCs in SCLC by both epitope-dependent
and -independent enrichment techniques. Two other studies
have assessed the expression of PD-L1 on CTCs in SCLC
patients finding PD-L1 expression in 0–50% of samples
(49,51). In our study, ≥2 PD-L1+ CTCs were detected in
7/23 (30.4%) samples regardless of the isolation method.
This discrepancy could be attributed to the antibody
clones utilised, especially the high sensitivity of the PD-L1
antibody clone (28.8) or TSA amplification of the antibody
signal for PD-L1 detection in our study.
The present study has some limitations such as the
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fact that the study population was small with an inferred
post-hoc power of 0.36, which hindered the feasibility of
inferential statistics. In particular, the inclusion of a small
number of patients treated with chemotherapy alone did
not enable an analysis of the predictive value of PD-L1
expressing CTC for response to treatment as shown for
other cancers (37,56,57). It was not possible to assess the
association of PD-L1+ CTCs with survival among patients
treated with immunotherapy, given their small number of
cases (9 of 21) in this subgroup. Finally, PD-L1 expression
assessment is not a routine practice for SCLC. Thus, we
could not compare the expression of PD-L1 on CTCs to
that of the matching tumours as samples were not available
for evaluation.
Conclusions
The current findings extend our knowledge of the ability
of epitope-independent technologies to detect subsets of
CTCs. The study demonstrates that PD-L1 expression can
be quantified on CTCs detected in SCLC patients. This
could potentially serve as a marker to evaluate the likelihood
of anti-PD-1 therapy response.
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Appendix 1
Cell lines
Carcinoma-derived cell lines MCF7 and MDA-MB-231 (breast cancer), and LNCaP acquired from ATCC (ATCC,
Manassas, VA, USA) were maintained in cell culture media as a monolayer at 37 ℃ with 5% CO2 in humidified air. LNCaP
cells were cultured in RPMI 1640 (ThermoFisher Scientific, Waltham, MA, USA), containing 10% foetal bovine serum
(FBS) (ThermoFisher Scientific). MDA-MB-231 and MCF-7 cell lines were cultured in DMEM (ThermoFisher Scientific)
containing 10% FBS. Cells were harvested at 80% confluency for flow cytometry and immunofluorescent staining. Some
MCF7 cells were incubated with 100 ng/mL IFN-γ for 24 hours to induce PD-L1 expression.
Antibody purification, immunomagnetic beads coupling, and recovery assessment
Anti-EpCAM antibody (Ber-EP4, ab7504, Abcam) was purified using the NAb Spin Kits, 0.2 mL (ThermoFisher Scientific)
following the manufacturer’s instructions. Purified Anti-EpCAM antibody was covalently bound to magnetic beads using a
Dynabead Antibody Coupling Kit (ThermoFisher Scientific) following the manufacturer’s instructions. Purified antibody was
quantified using a NanoDrop One (ThermoFisher Scientific); 3 μg of antibody was used per mg of Dynabeads M-270 Epoxy.
Antibody coupling with the Dynabeads was confirmed using flow cytometry. For this, two microlitres of coated beads were
added to 500 μL of phosphate-buffered saline (PBS) and incubated for 15 minutes at room temperature with a donkey antimouse IgG antibody conjugated to Alexa Fluor 488 (Abcam USA) diluted 1/500. After washing, beads were analysed using
a Gallios Flow Cytometer (Beckman Coulter, Brea, CA, USA). Unlabelled EpCAM-coated beads were used as a negative
control.
We assessed the performance of the EpCAM-coated magnetic beads and obtained 82% recovery efficiency using LNCaP
cell lines (expressed EpCAM and CK), pre-labelled with 1 µL of CellTracker Red (ThermoFisher Scientific) spiked into
peripheral blood mononuclear cells (PBMCs) obtained from healthy donors.
Assessment of PD-L1 expression by flow cytometry
PD-L1 expression for each cell line was initially assessed by flow cytometry using a Gallios Flow Cytometer (Beckman
Coulter) with the 28.8 PD-L1 antibody clone (Abcam, Cambridge, UK). Ten thousand cells were suspended in 100 μL of
stain buffer [1% bovine serum albumin (BSA)/10% normal donkey serum (NDS) in PBS] containing PD-L1 diluted 1/100
for 30 minutes. The cells were then washed once with 0.5% BSA in PBS before resuspending in stain buffer containing a
secondary donkey anti-rabbit IgG antibody conjugated to Alexa Fluor® 488 (Abcam) diluted 1/500 for 30 minutes. The cells
were once again washed once in 0.5% BSA in PBS before being resuspended in 100 μL of stain buffer and analysed using a
Gallios Flow Cytometer (Beckman Coulter). Fluorescence values obtained for each cell line were then compared to form a
relative scale which was utilised to identify high, low, and negative PD-L1 expressing cell lines which were subsequently used
as controls Figure S1.
MDA-MB-231 cells constitutively expressed high levels of PD-L1, with a 9.2-fold shift in median fluorescence intensity
relative to the isotype control. LnCAP cells had no apparent shift in median fluorescence intensity. MCF7 cells incubated
with 100 ng/mL of IFN-γ for 24 hours had a 3.7-fold shift in median fluorescence intensity relative to the primary control.
Therefore, MDA-MB-231 cell line was selected as the high expression control, IFN-γ induced MCF7 was selected as the low
expression control and LnCAP was selected as the negative control.
Assessment of PD-L1 expression on cells captured using anti-EpCAM coated magnetic beads
Peripheral blood mononuclear cells (PBMCs) were isolated from blood by density gradient centrifugation over Ficoll-Paque
(GE Healthcare Biosciences, Uppsala, Sweden) and resuspended in 1 mL MACS buffer (0.5% BSA, 2 mM EDTA in PBS,
pH 7.2). Healthy control PBMC spiked MCF-7, induced with IFNγ to express PD-L1, was then isolated using 3 μL EpCAM
antibody conjugated magnetic beads. Captured cells were quenched for endogenous peroxidase activity with 0.3% H2O2 for
© Translational Lung Cancer Research. All rights reserved.
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20 minutes before incubated for 1 hour at room temperature with anti-pan cytokeratins, WBC marker, and unconjugated
anti-PD-L1 antibody (Table S1) and then placed on a magnetic for 2 minutes. The resulting pellet was washed twice with
PBS then incubated in stain buffer containing anti-rabbit horseradish peroxidase (HRP) (1/200, Perkin Elmer) for 30 minutes.
Cells were again washed with PBS before incubating in TSA Plus working solution (TSA plus Cy5 kit, Perkin Elmer) for
5 minutes. The cells were once again washed with PBS and then placed on a magnetic. The resulting pellet was mounted with
Fluoromount Gold plus DAPI (ThermoFisher Scientific). Tyramide signal amplification (TSA) was introduced to increase the
signal for PD-L1 detection. Slides were visualised and scanned using a Nikon Eclipse Ti-E inverted fluorescent microscope.
Images were analysed using the NIS-Elements Analysis software, version 5.21. Examples in Figure S2.
Carcinoma immunocytochemistry assay for PD-L1 expression on cytospun cells
MDA-MB-231 (strong PD-L1 expression), IFN-γ induced MCF-7 (weak PD-L1 expression), MCF7 (negative PD-L1
expression) cell line spikes were analyzed for PD-L1 expression. After collection, cell line spikes were immediately fixed in
4% paraformaldehyde (PFA) for 10 minutes. After that, cells were cytospun using Cytospin™ 4 (Thermo Fisher Scientific)
onto glass slides at 2,000 rpm for 5 minutes at medium acceleration. Cells were then dried, and slides stored in a desiccator
at 4 ℃ or progressed straight to staining. Cells were incubated in blocking buffer (10% NDS/10% Glycine/5% Human FcR
block/3% BSA/0.2% TX in PBS) for 15 minutes before incubating in stain buffer (10% NDS/3% BSA/0.2% TX in PBS)
containing pan-cytokeratins, WBCs markers (Table S1) for 1 hour. Following this incubation cells were washed in 1% BSA in
PBS followed by washes in PBS. They were then incubated with 2 µL/mL of the nuclei staining dye solution, Hoechst 33342
(Thermo Fisher Scientific), for 15 minutes and finally wash with PBS.
A silicon isolator was immediately placed on the glass slide encircling the area where the cells were located. PBS (200 µL)
was added to the space containing the cells, and the cells were immediately visualized and scanned using an inverted
fluorescent microscope (Eclipse Ti-E, Nikon®, Japan). Images were analysed using the NIS-Elements High Content Analysis
software, version 4.2.
After microscopy, the silicon isolator was removed, slides were washed five times for 5 minutes each in PBS before incubation
in freshly prepared 1 mg/mL NaBH4 in PBS solution for 180 minutes, with the NaBH4 in PBS solution being replaced with
fresh solution after 90 minutes. Slides were then washed five times for 5 minutes each in PBS before incubating in 100 mM
tris solution for 1 hour. Slides were once again washed three times for 5 minutes each in PBS before quenching endogenous
peroxidase activity with 0.3% H2O2 for 20 minutes. Slides were incubated in blocking buffer for 15 minutes before incubating
in stain buffer containing PD-L1 (clone 28.8, Abcam) and Alexa Fluor 647 labelled anti-vimentin for 1 hour.
Slides were then washed three times with 1% BSA in PBS for 5 minutes each and then incubated in stain buffer containing
anti-rabbit HRP (1/200, Perkin Elmer) for 30 minutes. Slides were again washed three times with 1% BSA in PBS for
5 minutes each before incubating in TSA Plus working solution (TSA plus Cy5 kit, Perkin Elmer) for 5 minutes. Finally,
slides were once again washed three times with 1% BSA in PBS for 5 minutes each, washed once in PBS for 5 minutes, dried
and mounted with Fluoromount Gold plus DAPI (ThermoFisher Scientific) for re-imagining.
MCF7 cells demonstrated strong CK/EpCAM staining and no detectable vimentin staining while MDA-MB-231 cells
demonstrated weak CK/EpCAM staining and strong vimentin staining. PD-L1 was expressed at low levels in the IFN-γ
induced MCF7 cells and strongly expressed in the MDA-MB-231 cells. All MCF7 cells, both IFN-γ induced and not, and
all MDA-MB-231 cells were negative for the WBC markers CD16, CD66b, and CD45. This protocol was applied for the
analysis of CTCs enriched using the Parsortix system (Figure S3).
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Figure S1 Histogram plots from flow cytometric analysis of PD-L1 expression on MCF7 cells (A), MDA-MB-231 cells (B) and LNCaP
cells (C) using the 28.8 antibody diluted 1/100 with AF488 conjugated donkey anti-rabbit secondary antibody diluted 1/500. Cells stained
with donkey anti-rabbit secondary antibody, but no primary antibody, were used as controls. MCF7 cells were analysed with and without
induction of PD-L1 expression by incubation with IFN-γ for 24 hours.

Table S1 Antibodies used for immunocytochemistry staining
Antibody

Host species Conjugate

Clone

Antigen location Supplier (CTLG no.)

CD16

Mouse

AF647

3G8

Membrane

BioLegend USA, (302008)

1/50

WBC identification

CD45

Mouse

AF647

HI30

Membrane

BioLegend USA (304018)

1/50

WBC identification

CD66b

Mouse

AF647

G10F5

Membrane

BioLegend USA (305110)

1/100

WBC identification

Cytokeratins

Mouse

FITC

CK3-6H5

Cytoskeleton

Miltenyi Biotech Gladbach,
Germany (130-118-964)

1/50

CTC identification

Cytokeratins

Mouse

AF488

C11

Cytoskeleton

Cell Signalling Technology,
USA (4523S)

1/100

CTC identification

Cytokeratins

Mouse

AF488

AE1/AE3

Cytoskeleton

ThermoFisher Scientific,
USA, (53-9003-80)

1/200

CTC identification

EpCAM

Mouse

PE

VU-1D9

Membrane

ThermoFisher Scientific,
USA, (MA1-10197)

1/100

CTC identification

Vimentin

Mouse

AF647

V9

Cytoskeleton

Abcam, USA, (ab195878)

1/1,000

CTC identification

PD-L1

Rabbit

n/a

28.8

Membrane

Abcam, USA, (ab205921)

1/400

PD-L1 expression

HRP

Rabbit

n/a

n/a

Perkin Elmer

1/200

Signal amplification

TSA plus Cy5 kit, Perkin
Elmer

1/50

Signal amplification

TSA

Dilution

Use

AF, Alexa Fluor; WBC, white blood cells; CTC, circulating tumour cell; PE, phycoerythrin; HRP, horseradish peroxidase.
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Figure S2 Immunofluorescence staining of beads recovered cells. Representative images of IFN-γ induced MCF7 cells (A), non-induced
MCF7 cells (B), LnCaP cells (C) and WBCs (D). Cells were stained with antibodies targeting mixed pan-cytokeratins (pCK, green), AF647
CD45/CD16/CD66b (pink), PD-L1 expression (cyan), DAPI for nuclei staining (blue), Scale bar (top left) represents 10 μm. WBCs, white
blood cells.
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Figure S3 PD-L1 staining controls. Representative images depicting MDA-MB-231 cells (A), IFN-γ induced MCF7 cells (B) and MCF7
cells (C) immune staining with the final carcinoma panel. Cells were stained with FITC/AF488 mixed pan-cytokeratins and EpCAM (green),
AF647 CD45, CD16 and CD66b (red), AF647 vimentin (purple) and Cy3 TSA PD-L1 (cyan). Scale bar (top left) represents 10 μm.
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Figure S4 Representative images showing clustered CTC-WBC cells enriched with Parsortix system from SCLC patient blood samples.
Cells were stained with FITC/AF488 mixed pan-cytokeratins (green), PE-EpCAM (red), CD45/16/66b AF647 (pink) to identify classical
SCLC CTCs, followed by fluorescence quenching and re-immunostained for PD-L1 expression (cyan) and vimentin (orange). Clusters of
CTCs and leukocyte, Scale bar (top left) represents 10 μm. CTC, circulating tumour cell; WBCs, white blood cells; SCLC, small-cell lung
cancer.

Figure S5 Distribution of EpCAM-positive and negative CTCs enriched by Parsortix. The number of CTCs isolated in matching samples
using anti-EpCAM antibody-coated beads were indicated for comparison. Patient 1471 had EpCAM-positive CTCs. CTCs, circulating
tumour cells.
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Table S2 Association of CTCs thresholds with clinical characteristics (n=21)
Variables

2-CTCs threshold

50-CTCs threshold

<2 CTCs (n=9)

≥2 CTCs (n=12)

<50 CTCs (n=15)

≥50 CTCs (n=6)

<67

5 (55.6)

4 (33.3)

6 (40.0)

3 (50.0)

≥67

4 (44.4)

5 (66.7)

9 (60.0)

3 (50.0)

Age group (years)

P value

0.284

0.523

Gender
Female

6 (66.7)

6 (50.0)

6 (40.0)

3 (50.0)

Male

3 (33.3)

6 (50.0)

9 (60.0)

3 (50.0)

P value

0.377

0.523

Disease Stage
Limited

2 (22.2)

0 (0.0)

2 (13.3)

0 (0.0)

Extensive

7 (77.8)

12 (100.0)

13 (86.7)

6 (100.0)

P value

0.171

0.500

Performance status (ECOG)
0

3 (33.3)

6 (50.0)

7 (46.7)

2 (33.3)

1

3 (33.3)

5 (41.7)

5 (33.3)

3 (50.0)

≥2

3 (33.3)

1 (8.3)

3 (20.0)

4 (16.7)

P value

0.347

0.773

Number of metastasis
1

3 (33.3)

2 (16.7)

4 (26.7)

1 (16.7)

≥2

6 (66.7)

10 (83.3)

11 (73.3)

5 (83.3)

P value

0.353

0.550

Type of treatment
Chemotherapy

2 (22.2)

5 (41.7)

4 (26.7)

3 (50.0)

Chemotherapy + ICI

6 (66.7)

7 (58.3)

10 (66.7)

3 (50.0)

Radiation

1 (11.1)

0 (0.0)

1 (6.7)

0 (0.0)

P value

0.373

0.524

CTCs, circulating tumour cells; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor.
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Figure S6 Kaplan-Meier OS curves based on PD-L1 expression on CTCs among SCLC patients. CTCs, circulating tumour cells; CI,
confidence interval; HR, hazard ratio; OS, overall survival; SCLC, small-cell lung cancer.
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